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Abstract
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a result 
of metabolic changes that occur in patients with chronic kidney disease.  The 
consequences are renal osteodystrophy and vascular calcifications, especially seen 
in the more advanced stages of chronic renal failure. Different treatment regimens 
including dietary phosphate restriction, oral phosphate binders and active vitamin D 
supplementation have been used during the last 30 years.  Alfacalcidol (1a(OH)D3) is 
an analog of vitamin D3, a pro-drug of 1,25(OH)
2
D3, which is hydroxylated at position 
number 1 and therefore bypasses the impaired 1a-hydroxylation in the diseased 
kidneys of patients with chronic renal failure.  Alfacalcidol was the first vitamin D 
analog produced in the 1970’s, available for treatment of renal osteodystrophy in all 
stages of CKD. It has been used in most European countries since then, either alone or in 
combination with calcimimetics or bisphosphonates and shown to attenuate all aspects 
of CKD-MBD.
During the last 20 years, new vitamin D analogs with a potentially less effect 
on plasma calcium and phosphate and a more positive effect on the cardiovascular 
system have been on the market. None have demonstrated superiority compared to 
alfacalcidol. Based on the available clinical data, alfacalcidol can still be prescribed 
for treatment of secondary hyperparathyroidism in both early and late stages of 
CKD, besides being affordable to many patients, which is an important factor in many 
countries.
Hopefully, new drugs will be available in the future, which have positive effects on 
mortality and cardiovascular morbidity in CKD.
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ABBREVIATIONS BMD: Bone Mineral Density; CKD: Chronic Kidney Disease; CKD-MBD: Chronic Kidney Disease-Mineral and Bone Disorder; CVD: Cardiovascular Disease; FGF-23: Fibroblast Growth Factor 23; HPT: Hyperparathyroidism; HR-pQCT: High Resolution peripheral Quantitative Computed Tomography; KDIGO: Kidney Disease Improving Global Outcomes; PTH: Parathyroid Hormone; SHPT: Secondary Hyperparathyroidism; VDR: Vitamin D Receptor; VDRA: Vitamin D Receptor Activator; Wnt: Wingless-related Integration site
INTRODUCTIONChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) is a result of metabolic changes that occur in patients with chronic kidney disease (CKD).  The consequences are renal 
osteodystrophy and vascular calcifications, especially seen in the more advanced stages of CKD.  Different treatment regimens 
including dietary phosphate restriction, oral phosphate binders and active vitamin D supplementation have been used for the last 
30 years, and during the last 15 years calcimimetics have also 
become a part of the armamentarium [1].Current understanding 
of CKD-MBD suggests that calcium, phosphate, parathyroid 
hormone (PTH), fibroblast growth factor 23 (FGF-23) and vitamin D are key players in regulating mineral and bone metabolism. The factors are interrelated and their major target organs are the 
parathyroid glands, the kidneys, bone and the gastrointestinal 
tract (Figure 1). The increased levels of phosphate, PTH and FGF-23 contribute to the increased cardiovascular disease (CVD) 
in CKD [2,3]. Recent data has focused on the loss of klotho and crosstalk between bone and vessels as triggers for increased 
vascular calcification in CKD. The hypothesis is that bone affected 
by CKD predisposes to accelerated vascular calcification through the Wingless-related integration site pathway expressed by 
changes in sclerostin, osteocalcin, Dickkopf-related protein 
1and activin A [4-6]. In patients with CKD stage 5D and elevated 
or rising PTH, the KDIGO guidelines recommend: “calcitriol, 
or vitamin D analogs, or calcimimetics, or a combination of calcimimetics and calcitriol or vitamin D analogs to lower 
PTH”. In patients with CKD stage 3-5 not on dialysis, the KDIGO 
guidelines recommend: “in whom serum PTH is progressively 
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rising and remains persistently above the upper limit of normal 
for the assay despite correction of modifiable factors, we suggest 
treatment with calcitriol or vitamin D analogs” [7]. Repletion of 
25-hydroxy vitamin D (25-OH-D3) in patients with advanced CKD 
is still recommend, despite evidence for this being controversial 
[7-10].
The pro-drug alfacalcidol lisa analog of vitamin D, which is 
hydroxylated at position number 1 (Figure 2). Alfacalcidolhas 
the advantage of requiring only hydroxylation at the 25-position in the liver and in part locally in other tissues (e.g. bone) to 
become 1,25-hydroxy vitamin D (1,25(OH)2D3). Administration 
of alfacalcidol therefore bypasses the impaired 1α-hydroxylation 
in the diseased kidneys in patients with CKD [11].
Alfacalcidol was produced by LEO Pharma in 1973 as an oral 
formulation, which was convenient, stable and inexpensive [12]. Preliminary reports showed a therapeutic effect of alfacalcidol 
already in 1973 in rats and human [12] and the drug became 
available in Denmark in 1974 as the first and only vitamin D 
analog for clinical use. Since then, it has been the most used active vitamin D analog in Denmark and in most countries worldwide for prophylaxis and treatment of secondary hyperparathyroidism (SHPT) and renal osteodystrophy. Alfacalcidolis also approved 
for treatment of renal bone disease, different forms of 
osteomalacia and postmenopausal, glucocorticoid-induced and senile osteoporosis in most countries worldwide. The present article will focus on new knowledge about the pathogenesis of CKD-MBD and clinical use of alfacalcidol in CKD 
stage 3-5 and 5D, and whether newer vitamin D analogs provide further advantages in treatment of CKD-MBD compared to alfacalcidol.
REVIEW CRITERIA
A search for articles published between 2008 and 2016 focusing on alfacalcidol was performed in PubMed. The search 
terms used were “alfacalcidol”, “one-alpha” “vitamin D analogs”, 
“PTH”, “FGF23”, “phosphate”, “secondary hyperparathyroidism”, 
“CKD” and “human”, alone and in combination. All articles 
identified were English language, full-text papers. Reference 
lists of identified articles were also searched for further relevant papers.
CLINICAL USES OF ALFACALCIDOLMany different (mainly small) studies demonstrate an effect 
of alfacalcidol on both PTH level, bone and vessels. The effects of alfacalcidolas treatment and prophylaxis of SHPT in CKD 
patients on chronic dialysis are well documented [13,14]. Brandi 
et al., demonstrated that it was possible with both intravenous and oral administration of alfacalcidolto suppress PTH without 
inducing hypercalcemia, when plasma calcium was closely 
monitored and dose of alfacalcidolcarefully adjusted [13]. 
Gonzalez et al., demonstrated that intravenous administration of alfacalcidolsuppressed PTH at all levels of PTH in patients on chronic hemodialysis. The effect was greater at mild to 
moderate levels of PTH and therefore, initiation of therapy 
should be in the early stages of the SHPT [15]. Oral alfacalcidol 
also effectively suppressed PTH in children [16]. In 1995, the effect of oral alfacalcidol on bone was clearly demonstrated in a 
randomized controlled trial in CKD stage 3-4, by improving bone histology and preventing increases in alkaline phosphatases 
(Figure 3) [17]. In 2004, Rix et al., demonstrated that alfacalcidol 
improved Bone Mineral Density (BMD) and decreased PTH, 
osteocalcin and alkaline phosphatases (Figure 4) [18]. Further, 
in kidney transplant recipients, alfacalcidol in combination with bisphosphonate produced a superior effect on BMD compared 
the either of the two drugs alone [19]. In another study, Brandi et 
al., demonstrated an increase in BMD in dialysis patients treated 
within travenous alfacalcidol [13].
The main cause of mortality in CKD patients is CVD [20]. 
Therapies with active vitamin D and analogues, independent of 
Figure 1 Pathogenesis of secondary hyperparathyroidism in Chronic Kidney Disease – role of vitamin D.
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Figure 2 The chemical structure of the vitamin D analog alfacalcidol. 
Position 1 is marked with an arrow.
drug type, are associated with reduced mortality in CKD patients 
[21], in particular, those suffering from SHPT. These results, 
based on observational evidence, are supportive of prescribing 
vitamin D therapies to CKD patients, while respecting good 
practice guidelines [21]. In a large cohort of hemodialysis patient 
treatment with vitamin D receptor activators(VDRA), (type 
not further specified), the use of VDRAs was associated with a 
lower risk of incident CVD, but not with death from CVD [22]. As 
the vitamin D receptor (VDR) is expressed on cardiomyocytes, direct actions of vitamin D in the heart as a target organ are 
expected and demonstrated [23]. A retrospective study showed that oral administration of alfacalcidol for patients with CKD 
stage 3-5,was associated with reduced risk of CVD [24], similar 
to results presented in 2004 [25]. In CKD, low plasma levels 
of 1,25(OH)2D3 increases renal renin production. Activation 
of the renin-angiotensin-aldosterone system, in turn, reduces renal expression of klotho. The resulting high FGF-23 levels 
suppress 1-alpha hydroxylase and further lower1,25(OH)2D3 
[26]. In a retrospective study, treatment with alfacalcidol for 
SHPT reduced albuminuria by 16% in patients with CKD stage 
3-5 [27], probably by inhibition of the renin-angiotensin system. The combination of olmesartan and alfacalcidol inhibited the 
progression of renal damage in 5/6 nephrectomized rats through astrong antihypertensive effect as well as upregulation of klotho 
[28].
Figure 3 In a randomized clinical trial Hamdy et al., demonstrated that treatment with alfacalcidol corrects abnormal bone histology 
in mild to moderate renal failure [17]. Data kindly provided by LEO 
Pharma, Denmark.
Figure 4 In a randomized clinical trial Rix et al., demonstrated that treatment with alfacalcidol preserved bone mass in the spine and 
femur in mild to moderate renal failure [18]. Data kindly provided by 
LEO Pharma, Denmark.
In a hemodialysis population, treatment with alfacalcidol was 
associated with reduced development of vascular calcification as 
assessed by chest-x-ray [29]. 
Also, an open-label randomized clinical trial of alfacalcidol versus to no active vitamin D treatment in dialysis patients demonstrated that treatment with alfacalcidol had no effect 
on microvascular endothelial function in diabetic patients, but 
significantly improved central systolic blood pressure with trends toward improvement in arterial stiffness and peripheral blood 
pressure [30]. In  another study, intravenous administration 
of alfacalcidol reduced left ventricular mass index, but simultaneously left ventricular function became hyperdynamic 
and less effective [31]. In a single-center retrospective 
observational study, pharmacological doses of alfacalcidol were associated with accelerated progression of aortic stiffness. This study suggests that the vascular safety of active vitamin D may 
need to be specifically addressed in the treatment of CKD [32]. 
Another study of hemodialysis patients, the prescription of 
alfacalcidol was associated with lower pulse wave velocity [33]. 
PLEIOTROPIC EFFECTS OF ALFACALCIDOLVitamin D plays a role in the crosstalk between the innate and 
the adaptive immunity. The paracrine response of 1,25(OH)2D3 seems to have an effect on monocytes and immature dendritic 
cells. The local production of1,25(OH)2D3is assumed to enhance a tolerogenic immune response and possess immunosuppressive 
properties[34]. Therefore alfacalcidol could be interesting in 
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treatment of autoimmune diseases. A recent randomized clinical trial demonstrated a positive effect of alfacalcidol on multiple sclerosis-related fatigue compared to placebo. The kidney 
function was not described [35].
Further, increased insulin sensitivity in CKD and reduced need for erythropoietin stimulating agents (ESA)are reported 
with alfacalcidol [34]. Some older studies are also available 
regarding alfacalcidol and effects related to ESA treatment [36], 
immunity [37] and insulin resistance  [38] in CKD. 
ANALOGSThe dose limiting factors regarding active vitamin D for treatment of SHPT in CKD are hyperphosphatemia and 
hypercalcemia [1]. In a direct single-dose comparative set-
up, there was no difference in the PTH suppressive effect of 
alfacalcidol and 1,25(OH)2D3 following administration of 4 μg 
of the two drugs, while a smaller effect for alfacalcidol than 
1,25(OH)2D3 was seen following administration of 10 μg. The 
hypercalcemic effect was higher for 1,25(OH)2D3 than alfacalcidol 
[13]. The smaller clinical effect per dose was underlined in another 
more recent study [39]. The main reason for developing new vitamin D analogs was initially to produce drugs that suppressed 
PTH sufficiently, but with less development of hypercalcemia and hyperphosphatemia. Focus later expanded to all parts of 
the CKD-MBD syndrome such as renal osteodystrophy, vascular 
calcification and also non-classical vitamin D effects, especially 
in oncology and dermatology [40].  Paricalcitol was the first analog on the market with a suspected lower calcemic effect than 
1,25(OH)2D3. That drug nearly replaced 1,25(OH)2D3 in USA and other parts of the world and has been used intensively for the 
last 10 years [41]. A recent meta-analysis  between  paricalcitol and other active non-selective vitamin D receptors (including alfacalcidol) concluded that it was not possible to demonstrate 
any superiority of  paricalcitol [42]. In a randomized clinical trial 
set-up between alfacalcidol and 19-nor-D2the two drugs were equal for treatment of disturbances in mineral metabolism in hemodialysis patients. There was no difference regarding effect 
on PTH or safety profile [43]. Recently clinical data from a new vitamin D3 analog, 2 MD (a 19-nor-D3 analog), has been published 
[44,45]. Promising results are demonstrated, but a study including a control group treated with another active vitamin D analog is needed. An eight-week direct comparison between alfacalcidol 
and falecalcitriol has been performed in 1998. In that study, falecalcitriol was superior to alfacalcidol regarding suppression 
of PTH [46]. In a later study directly comparing falecalcitriol 
with calcitriol, no difference was found [47]. Vitamin D analogs 
available for use in CKD are described in Table (1).
DIFFERENT ROUTES OF ADMINISTRATION  Most active vitamin D analogs are available both as oral 
and intravenous formulation. The intravenous formulation of 
alfacalcidol was developed in the 1980’s. The first intravenous 
formulation of active vitamin D on the market was 1,25(OH)2D3. The intension was to enhance the delivery of the drug directly 
to the target, improve the effect and reduce side-effect such as hypercalcemia and hyperphosphatemia compared to oral 
administration [48]. To characterize the intravenous formulation 
of alfacalcidol, pharmacokinetic studies were performed. 
The plasma concentration of 1,25(OH)2D3 was higher after 
intravenous than oral administration of alfacalcidol [13,49], but 
not as high as after intravenous administration of 1,25(OH)2D3 
[13]. The long-term effect of intravenous administration of alfacalcidol has been intensively investigated. The suppressive 
effect on PTH was marked, with manageable effects on plasma 
calcium and phosphate [13]. The intravenous formulation is only 
useful for the hemodialysis patients, where it is administered at the end of each dialysis session. A single study compared daily 
oral alfacalcidol with intermittent intravenous alfacalcidol, and found that the effect of intermittent alfacalcidol on PTH suppression was faster in all patients and also greater in those 
patients with PTH between 200 and 500 pg/ml compared 
to higher levels [50]. Another group has tested regime with 
intravenous administration 1,2 or 3 times weekly and found no 
difference in the effect on PTH [51].  The dosing regime thereafter 
changed from daily to intermittent. During the recent years, direct comparative studies have been performed between intravenous and oral administration in patients on chronic hemodialysis of 
both alfacalcidol [13,52,53] and doxercalciferol (1-alpha-(OH)D2) [54]. The effects on PTH, calcium and phosphate were similar. 
Based on the available pharmacological and clinical data, the intravenous formulation is likely to be superior only in a highly selected group. 
From the patients perspective, the intravenous formulation could have a huge advantage.  Patients with CKD have an 
extremely high pill burden [55] and it is clearly documented that the adherence to medication decreases as the number of pills 
increases[55]. Poor compliance will presumably result in worse 
clinical outcomes. In this situation, intravenous administration easily overcomes the problem with adherence.  
FUTURE PERSPECTIVESSince vitamin D was introduced on the therapeutic arena in 
CKD, it has successfully been supplemented with calcimimetics 
for better control of SHPT [56,57]. An intravenous formulation of a new calcimimetic drug has been developed and is now FDA 
approved [58,59].  
Renal osteodystrophy is associated with 2- to 14-fold increased fracture risk compared to the general population 
[60]. Risk of fractures is also increased in kidney transplant 
Table 1: Native vitamin D and Vitamin D analogs available for clinical use in CKD.Native vitamin D Non-selective VDRA Non-selective VDRA Selective VDRA Selective VDRAD2–Ergocalciferol Doxercalciferol
1α(OH)D2 Paricalcitol19-nor-D2D3- Cholecalciferol Alphacalcidol
1α(OH)D3 Calcitriol1,25(OH)2D3 Maxacalcitol22-oxa-D3Falecalcitriol
26,27-F6-1,25(OH)2D3
2 MD
(19-nor-D3)
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recipients [61]. Proper screening and management of CKD bone complications is critical to improving clinical outcomes. Methods to establish the severity of osteoporosis in non-CKD patients are analysis of BMD. This method alone has not been of use in CKD and new promising methods are being explored. One of these is high-resolution peripheral quantitative computed tomography 
(HR-pQCT) [62], an imaging method that provides detailed images of bone geometry and microarchitecture. Bisphosphonate in combination with active vitamin D (including alfacalcidol) is standard treatment of osteoporosis in patients with normal 
kidney function, CKD stages 1-3, and kidney transplant 
recipients [61,63]. Due to the risk of a dynamic bone disease, 
bisphosphonate are not recommended in CKD stage 4-5 [63]. Newer anti-osteoporotic medications such as RANKL-ligands are currently under investigation.  A recent retrospective study in 
non-CKD patients with osteoporosis demonstrated a significantly higher increase in BMD of the femoral neck and distal forearm in patients treated by denosumab and alfacalcidol compared 
to denosumab and inactive vitamin D [64]. In prospective non-
randomized study in hemodialysis patients, it was found that 
the combination of denosumab and 1,25(OH)2D3 decreased PTH 
secretion and allowed supraphysiological doses of 1,25(OH)2D3 
[65]. In a “letter to editor”, experience, also in a hemodialysis population are published.  An increase in PTH has also been described with denosumab in combination with different active vitamin D analogs (including alfacalcidol) in hemodialysis 
patients, perhaps in response to calcium lowering by denosumab 
[66]. Further studies are awaited.The usefulness of biomarkers in clinical studies has been 
unclear and the findings so far remain inconclusive. Biochemical markers that might be valuable in evaluation of both vascular 
calcification and bone in CKD are now tested [4-6]. Sclerostin, a protein suppressing osteoblast activity and inhibiting bone 
formation, is associated with plasma level of 25-hydroxy vitamin Din patient both with normal kidney function and 
CKD. In hemodialysis patients with low PTH levels, sclerostin is associated with phosphate and FGF-23. New data is available 
for sclerostin on vascular stiffness [67] and fracture risk [68]. 
The influence of vitamin D treatment on the plasma levels of sclerostin is unknown.
CONCLUSION
Alfacalcidol was the first vitamin D analog available for 
treatment of renal osteodystrophy, a pioneer in the arena in the 
1970’s. In the CKD population the indication expanded to include 
treatment of SHPT and post-transplant osteoporosis. Further, it has been shown to attenuate both bone and vessel disease. More new vitamin D analogs are on the market today. This has increased the understanding of CKD-MBD and the role of vitamin D in this context. None of these new vitamin D analogs have been shown to have different effects than alfacalcidol in randomized 
clinical trials. Based on the available clinical data, alfacalcidol can still be prescribed for treatment of SHPT in both early and 
late stages of CKD.Because the drug is old and inexpensive, it is 
affordable to many patients in many countries. Hopefully, in the future newer drugs with effects on mortality and cardiovascular morbidity in CKD will be available.
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